Illumina to Offer $325M in Convertible Notes; Will Use $200M to Repurchase Shares | GenomeWeb
NEW YORK (GenomeWeb News) - Illumina plans to sell $325 million in convertible senior notes pay for corporate expenses, the company said today.
Illumina said it will use roughly $200 million of the proceeds to buy shares of its common stock in a private transaction, and some of the rest will go to pay the cost of the convertible transactions.
The notes will be due 2014 and upon conversion holders will receive cash value for the principal amount and any excess will be given in common stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.